Advertisement

Document › Details
Agilent Technologies Inc.. (3/2/20). "Press Release: Agilent and Visiopharm Co-promote Advanced Digital Precision Pathology Solutions". Santa Clara, CA & Copenhagen.
Agilent Technologies Inc. (NYSE: A) and Visiopharm today announced that they have entered a co-marketing agreement. The announcement is happening at the USCAP 109th Annual Meeting being held February 29 through March 5, 2020, in Los Angeles, CA.
Based on a joint vision of end-to-end quality and standardization of tissue diagnostics, the partnership will address the currently unmet needs of pathology labs around the world. The companies’ shared goal is to provide specific technologies, products, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.
Agilent and Visiopharm will co-market Visiopharm’s portfolio of artificial intelligence-driven pathology solutions.
“This partnership is an exciting step in our shared commitment in the fight against cancer,” said Simon Østergaard, Agilent vice president and general manager of the company’s pathology group. “Agilent’s market-leading portfolio of pathology staining management solutions combined with Visiopharm’s digital interpretation solutions will help facilitate improved patient care and diagnostic accuracy. Together we will tackle some of the most critical challenges faced by pathology labs and pave the way toward the fully digitalized lab of the future.”
“The transformation into next-generation precision pathology is important to realize the full potential of tissue pathology in this dawning era of personalized medicine,” said Michael Grunkin, CEO of Visiopharm. “This transformation requires a holistic approach to standardization along the entire diagnostic journey from biopsy to diagnosis. We are excited to be working with Agilent on precisely that. With their complementary product portfolio and longstanding legacy of innovation and quality in this field, we see a very strong match.”
The co-marketing relationship will result in offerings that will improve the standardization of pathology labs and accelerate accurate diagnoses for their patients. Digital pathology is the future, although many labs have waited to adopt it due to the lack of choices currently available and the expense of adoption. This effort will enable labs to gradually adopt digital technologies in a flexible and scalable manner.
About Visiopharm A/S
Visiopharm® is a world leader in AI-driven digital precision pathology software. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centres, and diagnostic pathology labs all over the world use Visiopharm’s technology for tissue-based research and diagnostics. Its solutions use the latest advancements in artificial intelligence and deep learning to make the most comprehensive, highly configurable, and accurate tissue mining tools available on the market today. Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses in more than 38 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in London, England, Munich, Germany, and Westminster, Colorado. Follow Visiopharm on LinkedIn and Twitter.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
Media Contacts
Naomi Goumillout
Agilent Technologies Inc
+1 978 314 1862
naomi.goumillout@aglient.com
Adrian Arechiga
Visiopharm
+45 88 20 20 88
aar@visiopharm.com
Record changed: 2023-06-05 |
Advertisement

More documents for Agilent (Group)
- [1] Agilent Technologies Inc.. (9/5/23). "Press Release: Agilent Names Philip Binns to Lead Life Sciences and Applied Markets Group". Santa Clara, CA....
- [2] Illumina, Inc.. (9/5/23). "Press Release: Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer". San Diego, CA....
- [3] Agilent Technologies Inc.. (9/4/23). "Press Release: Agilent and ACTRIS Partner to Accelerate Cell and Gene Therapy in Singapore". Singapore....
- [4] Agilent Technologies Inc.. (6/12/23). "Press Release: Agilent Introduces New Comprehensive GPC/SEC Solutions at HPLC 2023 Conference". Santa Clara, CA....
- [5] Synthego Corporation. (5/17/23). "Press Release: Synthego Announces Invalidation of Agilent Patents in CRISPR Dispute". Redwood City, CA....
- [6] Agilent Technologies Inc.. (4/12/23). "Press Release: Agilent and PathAI Partner to Deliver AI-Powered Assay Development Solutions for Biopharma Research and Clinical Applications". Santa Clara, CA....
- [7] Agilent Technologies Inc.. (3/22/23). "Press Release: Agilent Honored with Asia Pacific Bioprocessing Excellence Award 2023 for Analytical Services". Singapore....
- [8] Agilent Technologies Inc.. (3/10/23). "Press Release: Agilent Announces Digital Pathology Scanner Distribution Agreement with Hamamatsu". Santa Clara, CA....
- [9] Agilent Technologies Inc.. (3/9/23). "Press Release: Agilent Announces Acquisition of e-MSion, Early-Stage Company Behind ECD Technology that Helps Accelerate Drug Development". Santa Clara, CA....
- [10] Agilent Technologies Inc.. (3/8/23). "Press Release: Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine". Santa Clara, CA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement

» top